Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04634825 |
| Title | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | MacroGenics |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | POL | HUN | ESP | BGR | AUS |